文献速递腹部技术与安全CT

合成肿瘤细胞外容积作为结直肠肝转移患者治愈性肝切除前的预测生物标志物

Synthetic tumor extracellular volume as a predictive biomarker for colorectal liver metastasis patients prior to curative hepatectomy.
PubMed 文献 · Eur Radiol · 2025-03-24

本回顾性单中心研究纳入2013—2020年接受新辅助化疗后治愈性肝切除的结直肠肝转移患者209例,用新辅助化疗后增强CT计算合成细胞外容积(ECV),以约登指数确定21%为截断值,高ECV组总生存和无复发生存显著优于低ECV组,高ECV与改善的总生存(HR 0.55,95%CI 0.34-0.91)和无复发生存(HR 0.71,95%CI 0.52-0.97)独立相关。

要点

  • 合成ECV与常规ECV高度相关(r=0.996,p<0.0001),Bland-Altman偏倚仅0.007,无需血细胞比容即可计算。
  • 以21%为截断值,高ECV组总生存和无复发生存均显著高于低ECV组(p=0.019和p=0.015)。
  • 高ECV与同时性结直肠肝转移、含抗VEGF方案及RAS-BRAF突变显著相关(p=0.022、<0.001和0.003)。

核心结论

  • 合成ECV可帮助预测新辅助化疗后治愈性结直肠肝转移切除患者的总生存和无复发生存,可能是有用的影像生物标志物以进行风险分层。

研究设计与样本

  • 回顾性单中心研究,纳入2013—2020年接受新辅助化疗后治愈性肝切除的结直肠肝转移患者209例(中位年龄56岁,男119例),采用新辅助化疗后增强CT计算合成ECV和合成血细胞比容,以约登指数确定合成ECV截断值行分组,用Cox回归模型多变量分析总生存和无复发生存的预后因素。

诊断标准与关键数值

  • 合成ECV与常规ECV相关良好(r=0.996,p<0.0001),Bland-Altman分析偏倚=0.007;合成ECV最佳截断点为21%,高ECV组115例、低ECV组94例;高ECV组较低ECV组总生存和无复发生存显著更高(p=0.019和p=0.015);高ECV独立关联改善的总生存(HR 0.55,95%CI 0.34-0.91)和无复发生存(HR 0.71,95%CI 0.52-0.97)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study evaluated the prognostic value of synthetic tumor extracellular volume fraction (ECV) and its association with somatic gene alternations in patients with colorectal liver metastases (CRLM) receiving neoadjuvant chemotherapy.

METHODS: This retrospective single-center study included patients undergoing curative hepatectomy after neoadjuvant chemotherapy for CRLM (2013-2020). Contrast-enhanced computed tomography (CT) studies obtained after neoadjuvant chemotherapy were used to calculate synthetic ECV and synthetic hematocrit by linear regression analysis. Patients were grouped according to synthetic ECV cutoff point based on the Youden index. Multivariate analyses were performed with Cox regression models to analyze the prognostic factors of overall survival (OS) and recurrence-free survival (RFS).

RESULTS: A total of 209 patients (median age 56 years, 119 men) were enrolled. Synthetic ECV correlated well with conventional ECV (r = 0.996, p < 0.0001) with minimal bias, according to the Bland-Altman analysis (bias = 0.007). The optimal synthetic ECV cutoff point was determined to be 21%, with 115 patients having high ECV and 94 low ECV. Multivariable analysis for predicting high ECV demonstrated significant associations with synchronous CRLM, anti-VEGF agent-containing regimen, and RAS-BRAF mutation (p = 0.022, < 0.001, and = 0.003, respectively). OS and RFS were significantly higher in the high ECV group compared to the low ECV group (p = 0.019 and p = 0.015, respectively). High ECV was independently associated with improved OS (HR 0.55, 95% CI 0.34-0.91) and RFS (HR 0.71, 95% CI 0.52-0.97).

CONCLUSIONS: Synthetic ECV can help predict OS and RFS in patients undergoing curative-intent CRLM resection after neoadjuvant chemotherapy and could be a useful imaging biomarker to stratify risk.

KEY POINTS: Question There is a need for a biomarker predictive of treatment response after neoadjuvant chemotherapy, prior to curative-intent colorectal liver metastases. Findings Synthetic extracellular volume fraction can help predict overall and recurrence-free survival and is associated with somatic gene alterations. Clinical relevance Prognostic markers of response to neoadjuvant chemotherapy in curative-intent colorectal liver metastases include extracellular volume fraction. Synthetic extracellular volume fraction obviates the need for hematocrit; a simplification that is expected to streamline routine clinical practice.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Minamiguchi K, Maki H, Haddad A, et al. Synthetic tumor extracellular volume as a predictive biomarker for colorectal liver metastasis patients prior to curative hepatectomy. Eur Radiol. 2025. PMID: 40126606. doi:10.1007/s00330-025-11503-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。